文献速递免疫规划

接种三抗原乙型肝炎疫苗PreHevbrio后血清保护性抗体水平的持久性

The persistence of seroprotective levels of antibodies after vaccination with PreHevbrio, a 3-antigen hepatitis B vaccine.
PubMed 文献 · Vaccine · 2023-05-11

本研究评估了完成三抗原乙型肝炎疫苗(3A-HBV)或单抗原乙型肝炎疫苗(1A-HBV)全程接种且已获血清保护(抗-HBs ≥ 10 mIU/mL)的芬兰受试者抗体持久性。2.5年后,3A-HBV组保持血清保护的比例为88.1%(95%CI:84.1,92.2),高于1A-HBV组的72.4%(95%CI:66.6,78.3),p < 0.0001;3A-HBV组平均抗-HBs为1382.9 mIU/mL(95%CI:1013.8,1751.9),高于1A-HBV组的252.6 mIU/mL(95%CI:127.5,377.6),p < 0.0001。多变量logistic回归显示,仅第3剂后(第196天)抗体滴度较高与血清保护丧失风险降低显著相关。

要点

  • 2.5年后3A-HBV组血清保护率88.1%,高于1A-HBV组的72.4%(p < 0.0001)。
  • 3A-HBV组平均抗-HBs为1382.9 mIU/mL,高于1A-HBV组的252.6 mIU/mL(p < 0.0001)。
  • 仅第3剂后第196天抗体滴度较高与血清保护丧失风险降低显著相关。

核心结论

  • 接种3A-HBV后2.5年,血清保护性抗体持久性优于1A-HBV,且平均抗-HBs水平更高。

研究设计与样本

  • 本研究为3期试验(PROTECT)的子集分析,纳入芬兰已完成全程接种且血清保护(抗-HBs ≥ 10 mIU/mL)的受试者,共入组465/528例合格受试者(3A-HBV组244例,1A-HBV组221例),基线特征均衡。

主要发现

  • 2.5年后,3A-HBV组保持血清保护的比例为88.1%(95%CI:84.1,92.2),1A-HBV组为72.4%(95%CI:66.6,78.3),p < 0.0001。
  • 3A-HBV组平均抗-HBs为1382.9 mIU/mL(95%CI:1013.8,1751.9),1A-HBV组为252.6 mIU/mL(95%CI:127.5,377.6),p < 0.0001。
  • 多变量logistic回归分析(纳入年龄、疫苗、初始疫苗应答、性别和BMI)显示,仅第3剂后(第196天)抗体滴度较高显著降低血清保护丧失的 odds。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prevention of hepatitis B virus (HBV) infection by vaccination can potentially eliminate HBV-related diseases. PreHevbrio™/PreHevbri® is a 3-antigen (S, preS1, preS2) HBV vaccine (3A-HBV) recently licensed for adults in the US, EU and Canada. This study evaluated antibody persistence in a subset of fully vaccinated and seroprotected (anti-HBs ≥ 10 mIU/mL) Finnish participants from the phase 3 trial (PROTECT) of 3A-HBV versus single-antigen HBV vaccine (1A-HBV). 465/528 eligible subjects were enrolled (3A-HBV: 244; 1A-HBV: 221). Baseline characteristics were balanced. After 2.5 years, more 3A-HBV subjects remained seroprotected (88.1 % [95 %CI: 84.1,92.2]) versus 1A-HBV (72.4 % [95 %CI: 66.6,78.3)], p < 0.0001) and had higher mean anti-HBs [1382.9 mIU/mL (95 %CI: 1013.8,1751.9) versus 252.6 mIU/mL (95 %CI: 127.5,377.6), p < 0.0001]. In multiple variable logistic regression analysis including age, vaccine, initial vaccine response, sex and BMI, only higher post dose 3 (Day 196) antibody titers significantly reduced the odds of losing seroprotection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Vesikari T, Langley JM, Spaans JN, et al. The persistence of seroprotective levels of antibodies after vaccination with PreHevbrio, a 3-antigen hepatitis B vaccine. Vaccine. 2023. PMID: 37179167. doi:10.1016/j.vaccine.2023.05.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。